BiotechTube
Provirex

Provirex

Munich, Germany· Est.
provirex.de
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $2.5M

Overview

Provirex is a private, preclinical-stage biotech developing a novel gene therapy platform for HIV cure. Its technology is based on engineered recombinases, which offer nucleotide-precision excision of viral DNA without relying on error-prone cellular repair mechanisms, potentially offering a safer alternative to CRISPR-based approaches. The company is a spin-off from the Leibniz Institute of Virology (LIV) and has secured non-dilutive funding for platform expansion. Its near-term focus is advancing its lead HIV program while exploring applications in other viral diseases like HTLV-1.

Infectious DiseaseHIVHTLV-1

Technology Platform

Engineered site-specific recombinase platform (e.g., Brec1) for precise excision of integrated viral DNA without relying on host DNA repair mechanisms.

Funding History

1
Total raised:$2.5M
Seed$2.5M

Opportunities

The primary opportunity is addressing the massive, lifelong global market for HIV treatment with a potential one-time functional cure.
The recombinase platform also offers expansion potential into other viral diseases like HTLV-1 and could be leveraged for other precise genomic deletions beyond virology.

Risk Factors

High scientific risk regarding in vivo efficacy and safety of a novel gene therapy in humans.
Significant regulatory hurdles for a first-in-class curative approach.
Intense competition from other HIV cure strategies, including those from larger, well-resourced companies.

Competitive Landscape

Provirex competes in the HIV cure space with multiple approaches, including CRISPR-based gene editing (e.g., Excision BioTherapeutics), broadly neutralizing antibodies, latency reversing agents, and other gene therapies. Its recombinase technology differentiates on the basis of precision and a potentially superior safety profile by avoiding double-strand breaks and error-prone repair.

More companies in CRISPR / Gene Editing →More companies in Germany →